Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Still can't believe
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Jan 12, 2021 3:44pm
182 Views
Post# 32278314

RE:RE:RE:RE:Still can't believe

RE:RE:RE:RE:Still can't believe
themagicbox wrote: Anyones guess Marky. This is the 'wild card' factor. Like MUGS was saying, this corporate update was definitely not "comprehensive". Classic Dan imo, ugh. More optimistic now that Haut and Stauffer are on board though.

Dead money for now as there are no short term catalysts that I see. This is important to mention so that people are not bag holding, and can make more money elsewhere to reinvest back in ATE. Like I have mentioned before, dont look at the daily SP, itll bring nothing but frustration.
In the medium to long term (likely 6 months) we'll see action similar to last years SP of $7-$8.

Again I hope Im wrong. However, given ATE's track record, its motto is "good science takes time" haha.

I am still very much positive on the science. Not so much the financial structure. 


-------

Agreed ... it's frustrating.
But we're now entering a place we've never been before - we're negotiating with various companies and we know that ATE doesn't want to go into Phase 3 on its own.
We also know the family of drugs are impressive so it should get attention from many parties.

The rest if rather blurry ... hahaha!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities